Skip to main content
Erschienen in: Rheumatology International 10/2007

01.08.2007 | Original Article

Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity

verfasst von: Ehud Paz, Muhammed Adawi, Idit Lavi, Yehuda Mussel, Reuven Mader

Erschienen in: Rheumatology International | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the correlation between measurements of antinuclear antibodies serum levels by enzyme immunoassay (ANA-EIA), and the degree of systemic lupus erythematosus disease activity. To retest the performance of the test compared to measurement of antinuclear antibodies by immunofluorescence (ANA-IIF). Eighty-five sera from 71 patients with SLE were tested. Demographic, clinical, laboratory, and SLEDAI status were collected. The sera were tested for ANA-EIA and by ANA-IIF at 1:40 and 1:160 dilutions. Serum levels of ANA-EIA were compared to the overall SLEDAI score and to each of its components. A SLEDAI score of ≥6 was considered clinically significant. The sera of fifty-one healthy volunteers served as controls. Serum levels of ANA-EIA were significantly higher in patients with a SLEDAI score of ≥6 compared to the group of patients with a SLEDAI score of <6 (= 0.004). High serum levels of ANA-EIA correlated significantly with elevated anti DS-DNA antibodies (< 0.001), low C3 or C4 levels (< 0.001), pyuria (< 0.011), arthritis (= 0.019), and new rash (= 0.019). Levels of ANA-EIA were significantly higher in patients tested positive by IIF compared to those who tested negative. Higher serum levels of ANA-EIA correlated with clinically significant disease activity in patients with SLE. Higher serum levels of ANA-EIA also correlated with some single items of the SLEDAI. The results also reiterated the validity of ANA-EIA testing in patients with SLE. Further longitudinal studies are needed in order to test the hypothesis that serum ANA-EIA levels might reflect fluctuations in disease activity.
Literatur
1.
Zurück zum Zitat Reichlin M (1993) Autoantibodies to defined antigens in systemic rheumatic diseases. Bull Rheum Dis 42:4–6PubMed Reichlin M (1993) Autoantibodies to defined antigens in systemic rheumatic diseases. Bull Rheum Dis 42:4–6PubMed
2.
Zurück zum Zitat Von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:323–358CrossRef Von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:323–358CrossRef
3.
4.
Zurück zum Zitat Homburger HA, Cahen YD, Griffiths J, Jacob GL (1998) Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 122:993–999PubMed Homburger HA, Cahen YD, Griffiths J, Jacob GL (1998) Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 122:993–999PubMed
5.
Zurück zum Zitat Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M (1997) Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol 4:185–188PubMed Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M (1997) Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol 4:185–188PubMed
6.
Zurück zum Zitat Russell AS, Johnston C (2003) Relative value of commercial kits for ANA testing. Clin Exp Rheumatol 21: 477–480PubMed Russell AS, Johnston C (2003) Relative value of commercial kits for ANA testing. Clin Exp Rheumatol 21: 477–480PubMed
7.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Scaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Scaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
8.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
9.
Zurück zum Zitat Ramsey-Goldman R, Isenberg DA (2003) Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; SDI). Arthritis Rheum 49:S225–S233 Ramsey-Goldman R, Isenberg DA (2003) Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; SDI). Arthritis Rheum 49:S225–S233
10.
Zurück zum Zitat Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611PubMedCrossRef Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611PubMedCrossRef
11.
Zurück zum Zitat Bernardini S, Infantino M, Bellincampi L, Nuccetelli M, Afeltra A, Iori R et al (2004) Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay. Clin Chem Lab Med 42:1155–1160PubMedCrossRef Bernardini S, Infantino M, Bellincampi L, Nuccetelli M, Afeltra A, Iori R et al (2004) Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay. Clin Chem Lab Med 42:1155–1160PubMedCrossRef
12.
Zurück zum Zitat Kavanaugh A, Tomar R, Reveille J, Solomon DH, Henry HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab 124:71–81 Kavanaugh A, Tomar R, Reveille J, Solomon DH, Henry HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab 124:71–81
13.
Zurück zum Zitat Solomon DH, Kavanaugh AJ, Schur PH, The American College of Rheumatology ad hoc committee on immunologic testing guidelines (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434–444PubMedCrossRef Solomon DH, Kavanaugh AJ, Schur PH, The American College of Rheumatology ad hoc committee on immunologic testing guidelines (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434–444PubMedCrossRef
14.
Zurück zum Zitat Hyashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, et al (2001) Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay in 307 patients. Clin Chem 47:1649–1659 Hyashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, et al (2001) Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay in 307 patients. Clin Chem 47:1649–1659
15.
Zurück zum Zitat Bayer PM, Bauerfeind S, Blenvenu J, Fabien N, Frei PC, Gilburd B et al (1999) Multicenter evaluation study on new HEp-2 ANA screening enzyme immune assay. J Autoimmun 13:89–93PubMedCrossRef Bayer PM, Bauerfeind S, Blenvenu J, Fabien N, Frei PC, Gilburd B et al (1999) Multicenter evaluation study on new HEp-2 ANA screening enzyme immune assay. J Autoimmun 13:89–93PubMedCrossRef
16.
Zurück zum Zitat Lehmann HP, Fuhling I, Ott C, Hudepohl B, Haass M (2000) HEp-2 ANA EIA: a new fully automated assay for the screening of antinuclear antibodies. Isr Med Assoc J 2: 646–648PubMed Lehmann HP, Fuhling I, Ott C, Hudepohl B, Haass M (2000) HEp-2 ANA EIA: a new fully automated assay for the screening of antinuclear antibodies. Isr Med Assoc J 2: 646–648PubMed
17.
Zurück zum Zitat Nossent H, Rekvig OP (2001) Antinuclear antibody screening in this new millennium: farewell to the microscope? Scand J Rheumatol 30:123–126PubMedCrossRef Nossent H, Rekvig OP (2001) Antinuclear antibody screening in this new millennium: farewell to the microscope? Scand J Rheumatol 30:123–126PubMedCrossRef
18.
Zurück zum Zitat Bossuyt X (2000) Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies. Clin Chem Lab Med 38:1033–1037PubMedCrossRef Bossuyt X (2000) Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies. Clin Chem Lab Med 38:1033–1037PubMedCrossRef
19.
Zurück zum Zitat Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 50: 2048–2065PubMedCrossRef Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 50: 2048–2065PubMedCrossRef
20.
Zurück zum Zitat Spronk PE, Bootsma H, Kallenberg GG (1998) Anti DNA antibodies as early predictor for disease exacerbations in SLE: guidline for treatment? Clin Rev Allergy Immunol 16:211–218PubMed Spronk PE, Bootsma H, Kallenberg GG (1998) Anti DNA antibodies as early predictor for disease exacerbations in SLE: guidline for treatment? Clin Rev Allergy Immunol 16:211–218PubMed
21.
Zurück zum Zitat Esdale JM, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 39:370–378CrossRef Esdale JM, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 39:370–378CrossRef
Metadaten
Titel
Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity
verfasst von
Ehud Paz
Muhammed Adawi
Idit Lavi
Yehuda Mussel
Reuven Mader
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 10/2007
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0324-7

Weitere Artikel der Ausgabe 10/2007

Rheumatology International 10/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.